Celebrating Evolution and Innovation: Our look back at 2023 and ahead to 2024

Maria Thacker Goethe headshot

The life science industry and its innovations are always advancing, always evolving in a never ending quest to address unmet patient and clinical needs. Industry organizations like Georgia Bio may not experience the frequency of flux – driven in large part by new technologies – as the members and partner entities we serve, but when significant change is needed, we are committed to swift action.

Such was the case earlier this year when Georgia Bio returned to our core mission and re-established our independence as a 501(c)6 advocacy organization from the Center for Global Health Innovation. From our November 1st announcement, “The ‘re-emergence’ of Georgia Bio is an industry demand-driven development. Academic and industry life science leaders have told us directly that they need a strong advocacy organization around which to engage with each other and advance their priorities. Those industry leaders are also prepared to provide the financial support required for Georgia Bio to be the entity that provides those services.”

What other accomplishments can we as an organization and industry celebrate from 2023 and what do we look forward to in 2024? 

The Rural Teacher Training Initiative, a program administered by our BioEd Institute, launched its fifth year in September. RTTI provides hands-on, immersive science teacher professional development for rural Georgia teachers. Curriculum is built to highlight and leverage the biotechnology that exists within traditional science courses, including biology and AP biology, chemistry and AP chemistry, physics, environmental biology, agriculture and horticulture, physical science, and life science.

GIS Workshop participants

Funded by the State of Georgia, we have reached more than 52,000 students in 87 counties across the state through 370 educators who have participated in the program since its inaugural year, 2019. 70% of these educators and students teach and learn in Title I schools. 

RTTI 5.0 will have a Fall Training series followed by Spring Training Series. The Fall Series is virtual, live, hands-on, and will take place over four, two-hour sessions. Participants will be sent supplies to engage and practice during each session.


Back to the Summit!
Our Innovation Summit returned, this time hosted by our friends in Sandy Springs, bringing together more than 300 of our industry, advocacy and higher ed colleagues. Check out the highlights in our recap posts including BIO Board Chair Ted Love’s keynote, venture funding and AI & medtech sessions.

BioReady Communities logo

As part of the program, we celebrated Johns Creek and its certification as a BioReady Community, the first municipality in Georgia so designated. As just the second state in the country to formally adopt such a program, the BioReady Communities program will allow Georgia’s municipalities to showcase biotech-zoned science parks, streamline permitting, build a robust infrastructure, and identify biotech-friendly sites more effectively in the interest of attracting companies interested in relocating. Read more.

How about “Southeast Venture Investment”

In the interest of serving the life science ecosystem beyond our historic focus on pharma, ag tech, legislative affairs, education and workforce development, we worked closely with Life Science Nation to create and confirm RESI South. (In a peek behind the curtain, bringing these opportunities to the ecosystem don’t happen in a vacuum. It took the collective team six months to make the upcoming event opportunity real.)

RESI South 2024 banner

“Dennis Ford, CEO of Life Science Nation [stated], ‘I have seen firsthand the incredible opportunities abounding in the Southeast U.S. with a plethora of colleges, universities, and hospitals, fostering life science research and development. This is combined with an amazing array of incubators, accelerators, regional and governmental entrepreneurial programs, and world-class Bio Clusters supporting startups across all phases of development. LSN’s global partnering network wants to tap into these seven states’ technological and innovative firepower.’” The in-person piece of RESI South is March 24 at the Whitley Hotel in Atlanta. Follow Life Science Nation(and this space) for additional details.

Speaking of next year… 

One of our top priorities for 2024 will be supporting our industry colleagues and patient advocacy groups. As we wrote recently, “Americans want policymakers to see lowering out-of-pocket costs for health care as a top priority. Putting pharma and its innovators who invest billions of dollars in R&D for therapies that improve outcomes and save lives in villainous crosshairs is easy to understand and politically expedient, but misguided.

“In 2021, West Virginia became the first state in the nation to adopt ground-breaking legislation related to drug pricing and PBM transparency. The State of Georgia is considering HB343 in its upcoming legislative session, requiring insurers and their PBMs to share the savings they negotiate on medicines directly with patients.”

It is likely more states will consider similar legislation. In this “environment,” it has never been more important for pharma to clearly communicate the value of its therapies or to deliver those therapies with great efficiency.

You can learn more about how we support the industry through legislative affairs by reading out Legislative Watch publication that we issue during GA Session. Take a look at our policy priorities, including support for academic research institutions within the University System of Georgia that feed industry innovation here.

New Digs!

A big thank you to Eversheds Sutherland and Bill Warren for “hosting” our offices for the past seven years, Georgia Bio is now seeking a new home for 2024. Have space? Interesting in sharing? Contact Maria!

Telling our story

Mainstage at the GA Life Sciences Summit

During his Summit keynote, Dr. Ted Love emphasized the importance of ‘taking back our narrative’ as it relates to the beating pharma cos have taken in the drug price debate. Georgia Bio will endeavor to follow that lead by developing and sharing more content featuring our members, our partners, industry, advocate, legislative and education in the coming year. Our collective work matters to patients, to business, to our state and local economic growth and we intend to make sure the importance of that work, and its outcomes, is well known.

If you have a story you’d like to share or help tell, we welcome your ideas. Email admin@gabio.org.

Organizationally, we are adding three new committees to our roster: business strategy, medtech (as mentioned in our November 1 missive), and innovation and entrepreneurship. One of the innovation and entrepreneurship committee’s charges will be to support venture events and young company pitch events throughout the state. We are also preparing to launch a new “Fellows Program” which offers companies the opportunity to access Georgia Bio’s extensive services, benefits, and network to help them grow. The program offers a three-year membership providing early-stage life science, biotech, and medtech companies full access to the complete Georgia Bio portfolio of benefits, including the Georgia Bio purchasing consortium and discounted access to seminars, conferences, and networking events. 

Again, we encourage you to get in touch with insights on events, organizations, young companies or investors with whom we should be in touch or aware.

In closing: a few asks

We are a member-driven and funded organization. As such, we need your help to not only ensure you and your organization’s membership is accounted for in forward-facing budgets, but also to communicate our value and share our stories encouraging others to become members.

We commit to listening closely to our members and partners to best understand how we can deliver value for your membership and/or sponsorships in events like the Summit.

A few recommendations:

  • To our large institutions and enterprises: engage locally, keep a close eye on the Georgia legislative session and stay in touch. We are working to advance your mission in innovation and health. 
  • Smaller companies including life science startups of all disciplines: get engaged with our new committees, participate in the Business Solutions program to save money on everything from lab supplies to shipping, watch for RESI South registration details and jump in!
  • To all, ask about our new sponsor packages.
  • Patient advocates: help us help you tell your (our) story. Get in touch and we can add your story to our patient blog.
  • Higher ed colleagues: Assign faculty to directly engage with us regularly, especially for innovation inclined faculty. Because a huge portion of successful life science innovation that becomes commercially available is born in academic settings, our relationship with and advocacy for industry is more closely tied to your mission and success that you might think.
  • For all, engage with us on social media!

If you’ve made it this far, thank you for reading! Look out for an announcement of our 2024 Board of Directors in the new year.

The Georgia Bio team wishes you joyful, safe and restful holidays, and a healthy, prosperous new year.

If you’re not already doing so, we encourage you to register for our weekly newsletter and follow us on LinkedIn.

Attendees at BioSpark event
August 31, 2026
The White House, August 31, 2026 - ADVANCING MOST-FAVORED-NATION (MFN) PRICING: Today, President Donald J. Trump announced nine new agreements with pharmaceutical manufacturers to lower prescription drug prices for Americans in line with the lowest prices paid by other developed nations (known as the most-favored-nation, or MFN, price). The agreements bring the total number of pharmaceutical manufacturers with MFN deals to 26, covering 89% of the branded drug market. The nine manufacturers are comprised of mid-sized pharmaceutical companies, including Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB. The agreements reduce prices on drugs that treat numerous costly, chronic, and even rare diseases, including hemophilia, Parkinson’s disease, macular degeneration, glaucoma, liver disease, skin conditions, and various forms of cancer. The agreements will provide every State Medicaid program in the country access to MFN drug prices on products made by the nine companies, resulting in billions of dollars in savings for Americans and continuing President Trump’s historic efforts to strengthen the program for the most vulnerable. The agreements ensure foreign nations can no longer use price controls to freeride on American innovation by guaranteeing MFN prices on all new innovative medicines the nine companies bring to market. Each of these manufacturers has agreed to fundamentally rebalance international drug pricing by providing MFN pricing to American patients. BOLSTERING AMERICA’S PHARMACEUTICAL SUPPLY CHAINS AND RESERVES: These nine pharmaceutical manufacturers committed to invest at least $19.6 billion collectively in U.S. manufacturing in the near term. Additionally, as part of the MFN agreements, several companies are donating active pharmaceutical ingredients for key products to the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR) to reduce reliance on foreign nations and ensure the United States has an adequate supply of such products in the event of an emergency. UCB will contribute 163 tons of levetiracetam, an anticonvulsant used to control and prevent certain types of seizures, to the SAPIR. Sun Pharma will contribute 71.4 tons of clindamycin and 6.75 tons of doxycycline; both antibiotics to treat bacterial infections, to the SAPIR. Teva Pharmaceuticals will contribute 45 metric tons of metronidazole, an antibiotic and antiprotozoal used to treat certain bacterial and parasitic infections, and 4.8 tons of amlodipine, an antihypertensive drug, to the SAPIR. Astellas will contribute 25 kg of tacrolimus, an immunosuppressant used to prevent organ rejection in people who have had organ transplants, to the SAPIR. LOWERING COSTS FOR AMERICANS: President Trump’s decisive and historic actions are lowering drug prices for the American people. Since its February launch, patients have saved more than $700 million on medicines through TrumpRx, including massive discounts on some of the most popular and costly medications used to treat obesity and infertility. In July of 2026, senior citizens without access to GLP-1 coverage to treat obesity gained access for just $50 per month. In the two months since the launch of this program, over 500,000 seniors have saved a total of $216 million dollars on these life-changing medicines. The Council of Economic Advisers estimates the total savings from President Trump’s MFN deals to reach $600 billion over the next decade. DELIVERING ON PROMISES TO PUT AMERICAN PATIENTS FIRST: President Trump is delivering on promises for American patients, accomplishing historic wins that the political establishment did not believe were possible. On May 12, 2025, President Trump signed an Executive Order titled: “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients” directing the Administration to take numerous actions to bring American drug prices in line with those paid by similar nations. On July 31, 2025, President Trump sent letters to 17 of the leading pharmaceutical manufacturers outlining the steps they must take to bring down the prices of prescription drugs in the United States to match the lowest price offered in other developed nations. There are now MFN deals with each of those leading pharmaceutical manufacturers. On September 30, 2025, President Trump announced the first agreement, with the drug manufacturer Pfizer, to bring MFN prices to American patients. On December 1, 2025, the Office of the United States Trade Representative, the Department of Commerce, and the Department of Health and Human Services announced an agreement with the United Kingdom (U.K.) that will increase the net price of new prescription drugs by 25% in the U.K., helping ensure they pay their fair share for innovative medicines. On December 19, 2025, President Trump announced nine new agreements with major pharmaceutical companies. On February 5, 2026, President Trump launched TrumpRx.gov , where patients can access large discounts on many of the most popular and highest-priced medicines in the country, paying prices in line with the MFN price. As of today, August 31, the Administration now has agreements with Pfizer, Astra Zeneca, EMD Serono, Eli Lilly, Novo Nordisk, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, Sanofi, Johnson & Johnson, AbbVie, Regeneron, Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB. President Trump is calling on Congress to enact the Great Healthcare Plan , a comprehensive plan to lower drug prices, lower insurance premiums, hold big insurance companies accountable, and maximize price transparency. Source: Fact Sheet: President Donald J. Trump Announces Deal with Nine Additional Pharmaceutical Manufacturers to Lower Drug Prices for Americans – The White House
August 31, 2026
NexGard® Plus donation to Johns Creek Police Department K-9 officers marks the company's commitment to the community. JOHNS CREEK, Ga. (August 31, 2026)– Boehringer Ingelheim today celebrated the grand opening of its new U.S. Animal Health headquarters in Johns Creek, Georgia, marking a significant milestone in the company's commitment to innovation, talent, and the future of animal health. Johns Creek was selected for its access to talent in one of the region's fastest-growing life sciences and innovation corridors, and proximity to other Boehringer sites in Georgia. The grand opening brought together elected officials, community leaders, customers, partners, and employees to celebrate Boehringer's presence in Georgia and its purpose of Transforming Lives for Generations through science and innovation. “The animals we care for and the customers we serve are at the center of everything we do,” said Peter Ploeger, U.S. Animal Health Country Managing Director, Boehringer Ingelheim . “This headquarters was designed to bring our people together, inspire collaboration, and strengthen our ability to develop solutions that improve the lives of companion animals, livestock, and the people who care for them. We are proud to call Johns Creek home and excited about the impact we will create together.” The Johns Creek headquarters complements Boehringer's broader Georgia footprint, which includes research, development, and manufacturing operations in Athens and manufacturing operations in Gainesville. Together, these sites, combining manufacturing, innovation and commercial activities, underline the importance of the U.S. for the company, which continues to invest in Georgia operations to deliver solutions that advance animal health around the world, according to event remarks from Dr. Armin Wiesler, Member of the Board of Managing Directors, Animal Health Business Unit . Georgia and local leaders, including Select Fulton Director of Economic Development Samir Abdullahi, highlighted Boehringer Ingelheim's continued investment in Georgia and commitment to the Johns Creek community. “Georgia continues to attract world-class companies because of our skilled workforce, business-friendly environment, and commitment to innovation,” said Georgia Gov. Brian P. Kemp . “Boehringer Ingelheim's investment in Johns Creek, along with their strong support of First Lady Marty Kemp's animal welfare efforts and K-9 law enforcement officers, reinforces their commitment to being a long-term partner with the State of Georgia." As part of the grand opening celebration, Alexandra McMenamy, U.S. Animal Health, Head of Pet at Boehringer , joined Chief Mitchell and local officials in presenting a donation of NexGard® Plus parasite protection to the Johns Creek Police Department's K-9 Unit in recognition of the department's service to the community. “We are proud to welcome a company committed to the well-being of animals,” said Mayor John Bradberry . “Boehringer Ingelheim’s support of the Johns Creek Police Department’s K-9 Unit is greatly appreciated.” The donation, made just after International Dog Day (August 26), highlights the company's commitment to supporting both animal health and the communities where its employees live and work. 
August 21, 2026
Genetic Engineering & Biotechnology News (GEN) has named Georgia #4 among its “Next 5 States” for emerging U.S. biopharma clusters . The article highlights UCB’s planned $2 billion investment at in Gwinnett County, Micron Biomedical’s new Alpharetta facility, Manus Bio’s expansion in Augusta, Science Square, Emory University, the CDC — and Georgia Life Sciences’ 10-year Life Sciences Roadmap . This recognition is exciting. But even more importantly, it validates the work happening across our entire ecosystem — and perfect momentum as we head into the 2026 Georgia Life Sciences Summit next week. Read more by visiting: Next 10 U.S. Biopharma Clusters
MORE POSTS